<DOC>
	<DOCNO>NCT01752244</DOCNO>
	<brief_summary>Obesity-induced chronic inflammation key component pathogenesis insulin resistance . Mounting evidence demonstrate anti-inflammatory characteristic vitamin D. Although analogue vitamin D3 extensively use treatment various chronic inflammatory disease , knowledge , research conduct regard obesity . The aim double blind clinical trial study investigate whether alphacalcidol treatment obese subject affect insulin resistance . Moreover , evaluate pathway Vitamin D receptor ( VDR ) , Peroxisome proliferator-activated receptor gamma ( PPARγ ) eroxisome proliferator-activated receptor- coactivator-1 α ( PGC1α ) gene expression may lead insulin resistance follow treatment either alphacalcidol placebo .</brief_summary>
	<brief_title>Assessing Effects Alfacalcidol Intake Expression Involed Gene Metabolism Obese Subjects</brief_title>
	<detailed_description>Increasing evidence human population study animal research establish correlative well causative link chronic inflammation insulin resistance . The anti-inflammatory characteristic vitamin D demonstrate previous study . In addition role bone calcium metabolism , vitamin D demonstrate influential regulation different immune system function glucose homeostasis pathway . Although low level vitamin D show close correlation obesity , whether vitamin D deficiency cause consequence obesity remain unclear . It noteworthy several study demonstrate vitamin D deficiency associate increase resistance insulin . The biologic effect vitamin D primarily mediate via nuclear transcription factor , vitamin D receptor ( VDR ) , trigger expression vitamin D responsive gene . VDR express different immune cell monocytes , T-lymphocytes , granulocytes . It document VDR PGC-1α show overlap pattern expression . Furthermore , expression PGC-1α PPARγ regulate via environmental stimulus diet , could suggest function VDR function also alter response external stimulus . PGC-1α demonstrate particular importance amelioration increase insulin sensitivity . Accordingly , evaluate whether alphacalcidol treatment obese subject generally suffer low state chronic inflammation could affect insulin resistance , design current double blind clinical trial study compare effect alfacalcidol placebo serum glucose , 25-OH vitamin D , PTH , lipid profile level well Homeostatic model assessment ( HOMA ) quantitative insulin sensitivity check index ( QUICKI ) index marker insulin resistance . Furthermore , ass possible cross talk VDR PPARγ , gene expression VDR , PPARγ PGC1α evaluate follow course treatment either alphacalcidol placebo .</detailed_description>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<criteria>Age 2252 year Body mass index equal 30 Exclusion criterion : Acute chronic inflammatory disease History hypertension Alcohol drug abuse History condition affect inflammatory marker know cardiovascular disease Thyroid diseases Malignancies Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute chronic infection Hepatic renal disease Use PPARγ agonist drug</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>52 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Obesity , vitamin D analogue , VDR , PPARg , PGC1a</keyword>
</DOC>